Blog
RSS FeedPosted by Michael Wonder on 08 Sep 2022
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada
7 September 2022 - The country, with an increasing immunoglobulin usage rate, currently imports about 85% of its immunoglobulin demand for ...
Posted by Michael Wonder on 07 Sep 2022
Ongoing uncertainty about prices will deter new drug launches in Canada
7 September 2022 - Further delays in access or complete denials of access to innovative drugs will hurt even more Canadians ...
Posted by Michael Wonder on 01 Sep 2022
CADTH launches post-market drug evaluation program
1 September 2022 - CADTH is pleased to announce the launch of its new post-market drug evaluation program. ...
Posted by Michael Wonder on 01 Sep 2022
Vabysmo (faricimab injection) receives positive CADTH recommendation for the treatment of neovascular (wet) age-related macular degeneration in adults
1 September 2022 - Provincial jurisdictions will make the final decision on public reimbursement. ...
Posted by Michael Wonder on 31 Aug 2022
CADTH ruling on Spinraza (nusinersen) extinguishes hope for adults needing treatment for spinal muscular atrophy
30 August 2022 - CADTH recommends against reimbursement and access to potentially life-altering treatment for adult spinal muscular atrophy patients, discounting ...
Posted by Michael Wonder on 30 Aug 2022
Yukon woman paid $7,000 for private ketamine treatment, only to learn that the Yukon Government covers it
29 August 2022 - Evelyn Larson visited a private clinic in Saskatoon only to find the Yukon did cover the treatment ...
Posted by Michael Wonder on 18 Aug 2022
Canadians seek diabetes medication as replacement for weight loss drug during arrival delays
18 August 2022 - High demand in the United States for a new weight-loss medication has indefinitely delayed its arrival ...
Posted by Michael Wonder on 09 Aug 2022
Network collaborators announced for CADTH’s post-market drug evaluation network
8 August 2022 - CADTH is pleased to announce the successful collaborators of its inaugural Post-Market Drug Evaluation Network. ...
Posted by Michael Wonder on 09 Aug 2022
Introducing CADTH’s RWE Guidance Working Group
9 August 2022 - CADTH is pleased to announce the introduction of the Real-World Evidence Guidance Working Group. ...
Posted by Michael Wonder on 30 Jul 2022
Amylyx Pharmaceuticals announces Albrioza is now available in Canada for the treatment of amyotrophic lateral sclerosis
29 July 2022 - Amylyx Pharmaceuticals today announced that Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) is now commercially available in Canada for ...
Posted by Michael Wonder on 25 Jul 2022
HLS announces that Vascepa is now reimbursed by Ontario's Provincial Drug Plan
25 July 2022 - Reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private ...
Posted by Michael Wonder on 18 Jul 2022
More children now eligible for cystic fibrosis drug
18 July 2022 - Effective today, the Province will pay for the cystic fibrosis drug Trikafta for children aged six to ...
Posted by Michael Wonder on 13 Jul 2022
Canada making progress in prescription drug coverage
13 July 2022 - Canada has seen a significant improvement in the number of Canadians eligible for some form of prescription ...
Posted by Michael Wonder on 12 Jul 2022
Alberta expands access to cystic fibrosis drug Trikafta for children 6 to 11
11 July 2022 - Children with cystic fibrosis can now live 'longer, healthier and fuller lives,' says advocate. ...
Posted by Michael Wonder on 11 Jul 2022
CADTH Advisory Panel report recommends framework for potential pan-Canadian formulary
11 July 2022 - In July 2021, the Government of Canada approached CADTH to develop a recommended framework for creating and ...